Warning: Creating default object from empty value in /var/www/wp-content/themes/shuttle-pro/shuttle-pro/admin/main/inc/class.redux_filesystem.php on line 29
Synthonics, Inc. - Metal Coordinte Pharmaceuticals

LATEST PRESS RELEASES

Phase 1 Clinical Trial of Poly-Zinc-Liothyronine Demonstrates Slow-Release Serum T3 Kinetics

January 4, 2022


EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANS

June 14, 2021


SYNTHONICS, INC.

Synthonics, Inc. is a privately-held specialty pharmaceutical company focused on the discovery and development of patentable drugs that incorporate our proprietary metal coordination chemistry. We bind metals to known pharmaceutical agents to create new products that are better absorbed and thus have greater therapeutic benefits than their predecessors. Although our chemistry has broad application, we are focused primarily on drugs, such a levodopa for Parkinson’s disease and T3 for hypothyroidism, whose rapid absorption limits their utility.


TECHNOLOGY
We attach a metal, such as zinc or bismuth, to a known drug to create a new, patentable compound with improved pharmacokinetics and performance. By varying the metal and means of attachment, we can impart a wide range of pharmacokinetic enhancements, such as greater solubility, permeability or mucoadhesion, to increase a drug’s safety, efficacy or tolerability.